Newsfeeds - Spark Newswire

2 minute read

Valneva Reports Revenues Of €361.3M In 2022 Compared To €348.1M In 2021, An Increase Of 3.8%

Today, 11:44 AM

Saint-Herblain (France), February 16, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA) a specialty vaccine company, today reported its revenue and cash balance for the full year 2022 and provided

PARIS:VLA

1 minute read

Valneva Priced 21M Share Global Offering of American Depositary Shares @$9.51/ADS

By Charles Gross

Today, 11:44 AM

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today the pricing of 21,000,000 ordinary shares in a global offering to specified categories of investors comprised of a public offering of 375,000 American Depositary Shares ("ADSs"), each representing two ordinary shares, in the United States (the "U.S.

PARIS:VLA

4 minute read

Valneva Announces Launch Of Approximately $40 Million In Proposed Global Offering Of American Depositary Shares, Ordinary Shares

By Michael Horton

Today, 11:44 AM

Valneva SE (NASDAQ:VALN, PARIS:VLA) (the "Company"), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its

PARIS:VLA

1 minute read

FDA
News

Valneva Receives Positive CHMP Opinion For Marketing Authorization Of Its Inactivated Covid-19 Vaccine Candidate In Europe

By Benzinga Newsdesk

Today, 11:44 AM

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing

PARIS:VLA

4 minute read

Valneva And Pfizer Report Phase 2 Pediatric Data For Lyme Disease Vaccine Candidate

By Bill Haddad

Today, 11:44 AM

Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in

PARIS:VLA

3 minute read

Valneva Confirmed Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

By Charles Gross

Today, 11:44 AM

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

DVAX

Latest news

Valneva Reports Revenues Of €361.3M In 2022 Compared To €348.1M In 2021, An Increase Of 3.8%

Valneva Priced 21M Share Global Offering of American Depositary Shares @$9.51/ADS

Valneva Announces Launch Of Approximately $40 Million In Proposed Global Offering Of American Depositary Shares, Ordinary Shares

Valneva Receives Positive CHMP Opinion For Marketing Authorization Of Its Inactivated Covid-19 Vaccine Candidate In Europe

Valneva And Pfizer Report Phase 2 Pediatric Data For Lyme Disease Vaccine Candidate

Valneva Confirmed Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001